Document is current
Any future updates will be listed below
-
Authors
Huber, Florian https://orcid.org/0000-0002-2585-9079
Arnaud, Marion https://orcid.org/0000-0003-0534-2379
Stevenson, Brian J.
Michaux, Justine
Benedetti, Fabrizio https://orcid.org/0000-0002-9959-9142
Thevenet, Jonathan https://orcid.org/0009-0008-1505-8068
Bobisse, Sara
Chiffelle, Johanna https://orcid.org/0000-0002-8312-2681
Gehert, Talita
Müller, Markus https://orcid.org/0000-0003-0907-3583
Pak, HuiSong
Krämer, Anne I.
Altimiras, Emma Ricart
Racle, Julien https://orcid.org/0000-0002-0100-0323
Taillandier-Coindard, Marie
Muehlethaler, Katja
Auger, Aymeric
Saugy, Damien
Murgues, Baptiste
Benyagoub, Abdelkader
Gfeller, David https://orcid.org/0000-0002-3952-0930
Laniti, Denarda Dangaj
Kandalaft, Lana https://orcid.org/0000-0002-1575-6674
Rodrigo, Blanca Navarro
Bouchaab, Hasna
Tissot, Stephanie https://orcid.org/0000-0003-3080-4598
Coukos, George https://orcid.org/0000-0001-8813-7367
Harari, Alexandre https://orcid.org/0000-0002-1055-2090
Bassani-Sternberg, Michal https://orcid.org/0000-0002-1934-954X
-
Funding
Funding for this research was provided by:
Ludwig Institute for Cancer Research, Swiss Bridge Foundation Award
- License Information
-
More Information
Article History
Received: 4 December 2023
Accepted: 4 September 2024
First Online: 11 October 2024
Competing interests
: G.C. has received honoraria from Bristol-Myers Squibb. CHUV has received honoraria for advisory services provided by G.C. to Iovance and EVIR. G.C. has received royalties from the University of Pennsylvania for CAR T cell therapy licensed to Novartis and Tmunity Therapeutics. G.C., A.H., M.A., S.B., F.H. and M.B.-S. have received royalties from the Ludwig Institute for Cancer Research, UNIL and CHUV for NeoTIL intellectual property previously licensed to Tigen Pharma. S.B., G.C. and A.H. are inventors in technologies related to T cell expansion and engineering for T cell therapy. F.H., M.M. and M.B.-S. are inventors on a patent application related to ML prioritization of neoantigens. F.H. and M.B.-S. are inventors on a patent application filed under certain subject matters disclosed herein. D.G. has received honoraria for consultations from CeCaVa and Gnubiotics. The other authors declare no competing interests.
